• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经两抗体鸡尾酒疗法对感染苏丹病毒的小鼠进行的暴露后保护。

Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail.

机构信息

US Army Medical Research Institute for Infectious Disease (USAMRIID), Fort Detrick, MD 21702, USA.

Unite de Biotechnologie des Anticorps, Institut de Recherche Biomedicale des Armees (IRBA-CRSSA), La Tronche 38516, France.

出版信息

Viruses. 2018 May 26;10(6):286. doi: 10.3390/v10060286.

DOI:10.3390/v10060286
PMID:29861435
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6024315/
Abstract

Sudan virus (SUDV) and Ebola viruses (EBOV) are both members of the genus and have been sources of epidemics and outbreaks for several decades. We present here the generation and characterization of cross-reactive antibodies to both SUDV and EBOV, which were produced in a cell-free system and protective against SUDV in mice. A non-human primate, cynomolgus macaque, was immunized with viral-replicon particles expressing the glycoprotein of SUDV-Boniface (8A). Two separate antibody fragment phage display libraries were constructed after four immunogen injections. Both libraries were screened first against the SUDV and a second library was cross-selected against EBOV-Kikwit. Sequencing of 288 selected clones from the two distinct libraries identified 58 clones with distinct V and V sequences. Many of these clones were cross-reactive to EBOV and SUDV and able to neutralize SUDV. Three of these recombinant antibodies (X10B1, X10F3, and X10H2) were produced in the scFv-Fc format utilizing a cell-free production system. Mice that were challenged with SUDV-Boniface receiving 100µg of the X10B1/X10H2 scFv-Fc combination 6 and 48-h post-exposure demonstrated partial protection individually and complete protection as a combination. The data herein suggests these antibodies may be promising candidates for further therapeutic development.

摘要

苏丹病毒(SUDV)和埃博拉病毒(EBOV)均属于丝状病毒属,几十年来一直是引发疫情和爆发的源头。我们在此介绍了针对 SUDV 和 EBOV 的交叉反应性抗体的产生和特性,这些抗体是在无细胞系统中产生的,可在小鼠中预防 SUDV。使用表达 SUDV-Boniface(8A)糖蛋白的病毒复制子颗粒对食蟹猴进行免疫。在四次免疫接种后,构建了两个独立的抗体片段噬菌体展示文库。两个文库首先针对 SUDV 进行筛选,第二个文库针对 EBOV-Kikwit 进行交叉筛选。对来自两个不同文库的 288 个选定克隆进行测序,确定了 58 个具有独特 V 和 V 序列的克隆。这些克隆中的许多都对 EBOV 和 SUDV 具有交叉反应性,并能中和 SUDV。这三种重组抗体(X10B1、X10F3 和 X10H2)以 scFv-Fc 形式利用无细胞生产系统进行生产。在暴露后 6 和 48 小时接受 100µg X10B1/X10H2 scFv-Fc 组合的接受 SUDV-Boniface 挑战的小鼠分别表现出部分保护和完全保护。本文的数据表明,这些抗体可能是进一步治疗开发的有前途的候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b3b/6024315/6d7e7a500abd/viruses-10-00286-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b3b/6024315/fa2b42fb9b52/viruses-10-00286-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b3b/6024315/2a3046f8efde/viruses-10-00286-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b3b/6024315/3d99a8f1d889/viruses-10-00286-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b3b/6024315/6d7e7a500abd/viruses-10-00286-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b3b/6024315/fa2b42fb9b52/viruses-10-00286-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b3b/6024315/2a3046f8efde/viruses-10-00286-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b3b/6024315/3d99a8f1d889/viruses-10-00286-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b3b/6024315/6d7e7a500abd/viruses-10-00286-g004.jpg

相似文献

1
Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail.经两抗体鸡尾酒疗法对感染苏丹病毒的小鼠进行的暴露后保护。
Viruses. 2018 May 26;10(6):286. doi: 10.3390/v10060286.
2
Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.基于痘病毒的埃博拉病毒表达 GP 和 VP40 蛋白疫苗候选物的免疫原性和疗效的差异。
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.00363-18. Print 2018 Jun 1.
3
Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.通过对转染色体牛进行DNA疫苗接种产生的人源多克隆抗体为小鼠提供暴露后针对致死性扎伊尔和苏丹埃博拉病毒的保护。
PLoS One. 2015 Sep 30;10(9):e0137786. doi: 10.1371/journal.pone.0137786. eCollection 2015.
4
A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses.一种由重组杆状病毒系统生产的嵌合苏丹病毒样颗粒疫苗候选物在小鼠和马中诱导特异性免疫应答。
Viruses. 2020 Jan 3;12(1):64. doi: 10.3390/v12010064.
5
Delayed treatment of cynomolgus macaques with a FVM04/CA45 monoclonal antibody cocktail provides complete protection against lethal Sudan virus infection.延迟使用 FVM04/CA45 单克隆抗体鸡尾酒治疗食蟹猴可提供针对致死性苏丹病毒感染的完全保护。
J Virol. 2024 Aug 20;98(8):e0124223. doi: 10.1128/jvi.01242-23. Epub 2024 Jul 16.
6
Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses.双特异性抗体为小鼠提供暴露后对埃博拉(扎伊尔型)和苏丹病毒的完全保护。
Sci Rep. 2016 Jan 13;6:19193. doi: 10.1038/srep19193.
7
Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.靶向丝状病毒糖蛋白内新型保守表位的猕猴单克隆抗体。
J Virol. 2015 Oct 14;90(1):279-91. doi: 10.1128/JVI.02172-15. Print 2016 Jan 1.
8
Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.委内瑞拉马脑炎病毒复制子颗粒疫苗可保护非人灵长类动物免受埃博拉病毒的肌肉内和呼吸道挑战。
J Virol. 2013 May;87(9):4952-64. doi: 10.1128/JVI.03361-12. Epub 2013 Feb 13.
9
Development of an antibody cocktail for treatment of Sudan virus infection.开发一种用于治疗苏丹病毒感染的抗体鸡尾酒。
Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3768-3778. doi: 10.1073/pnas.1914985117. Epub 2020 Feb 3.
10
Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.三价副流感病毒载体埃博拉病毒疫苗诱导的抗体介导的保护机制。
J Virol. 2019 Feb 5;93(4). doi: 10.1128/JVI.01845-18. Print 2019 Feb 15.

引用本文的文献

1
Antibody-Based Antigen Delivery to Dendritic Cells as a Vaccination Strategy Against Ebola Virus Disease.基于抗体的抗原递送至树突状细胞作为抗埃博拉病毒病的疫苗接种策略。
J Infect Dis. 2025 Apr 15;231(4):e615-e625. doi: 10.1093/infdis/jiae613.
2
Discovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection.发现纳米抗体Nanosota-EB1和-EB2作为抗埃博拉病毒感染的新型纳米抗体抑制剂。
PLoS Pathog. 2024 Dec 23;20(12):e1012817. doi: 10.1371/journal.ppat.1012817. eCollection 2024 Dec.
3
A Bivalent Adenovirus-Vectored Vaccine Induces a Robust Humoral Response, but Does Not Protect Cynomolgus Macaques Against a Lethal Challenge With Sudan Virus.

本文引用的文献

1
Post-exposure treatments for Ebola and Marburg virus infections.埃博拉病毒和马尔堡病毒感染的暴露后治疗
Nat Rev Drug Discov. 2018 May 4. doi: 10.1038/nrd.2018.73.
2
Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.一名人类幸存者的抗体确定了针对埃博拉病毒广泛保护的易损位点。
Cell. 2017 May 18;169(5):878-890.e15. doi: 10.1016/j.cell.2017.04.037.
3
Generation and characterization of protective antibodies to Marburg virus.针对马尔堡病毒的保护性抗体的产生与特性分析
双价腺病毒载体疫苗可诱导强烈的体液免疫反应,但不能保护食蟹猴免受苏丹病毒的致死性挑战。
J Infect Dis. 2024 Nov 15;230(5):1083-1092. doi: 10.1093/infdis/jiae056.
4
Antibody Phage Display Technology for Sensor-Based Virus Detection: Current Status and Future Prospects.基于抗体噬菌体展示技术的传感器病毒检测:现状与未来展望。
Biosensors (Basel). 2023 Jun 9;13(6):640. doi: 10.3390/bios13060640.
5
Adenovirus vector-mediated single chain variable fragments target the nucleocapsid protein of porcine epidemic diarrhea virus and protect against viral infection in piglets.腺病毒载体介导的单链可变片段靶向猪流行性腹泻病毒的核衣壳蛋白并保护仔猪免受病毒感染。
Front Immunol. 2023 Jan 24;14:1058327. doi: 10.3389/fimmu.2023.1058327. eCollection 2023.
6
Antibodies against Anthrax Toxins: A Long Way from Benchlab to the Bedside.抗炭疽毒素抗体:从实验室到床边的漫长道路。
Toxins (Basel). 2022 Feb 25;14(3):172. doi: 10.3390/toxins14030172.
7
STAT-1 Knockout Mice as a Model for Wild-Type Sudan Virus (SUDV).STAT-1 敲除小鼠作为野生型苏丹病毒(SUDV)的模型。
Viruses. 2021 Jul 17;13(7):1388. doi: 10.3390/v13071388.
8
Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.通过噬菌体展示技术开发用于诊断和治疗的针对传染病和毒素的重组抗体。
Front Cell Infect Microbiol. 2021 Jul 7;11:697876. doi: 10.3389/fcimb.2021.697876. eCollection 2021.
9
Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors.抗体 Fc 介导的效应功能与埃博拉病毒幸存者长期后遗症之间的关联。
Front Immunol. 2021 May 20;12:682120. doi: 10.3389/fimmu.2021.682120. eCollection 2021.
10
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.SARS-CoV-2 中和性人源重组抗体,来源于大流行前健康供体,结合 RBD-ACE2 界面。
Nat Commun. 2021 Mar 11;12(1):1577. doi: 10.1038/s41467-021-21609-2.
MAbs. 2017 May/Jun;9(4):696-703. doi: 10.1080/19420862.2017.1299848. Epub 2017 Mar 13.
4
Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.通过糖蛋白受体结合位点内独特暴露的表位对埃博拉病毒和苏丹病毒感染进行抗体治疗。
Cell Rep. 2016 May 17;15(7):1514-1526. doi: 10.1016/j.celrep.2016.04.026. Epub 2016 May 5.
5
Recent advances in the development of vaccines for Ebola virus disease.埃博拉病毒病疫苗研发的最新进展
Virus Res. 2016 Jan 4;211:174-85. doi: 10.1016/j.virusres.2015.10.021. Epub 2015 Oct 24.
6
Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E.人源化单链抗体片段-免疫球蛋白Fc段中和型肉毒杆菌神经毒素E的研发
PLoS One. 2015 Oct 6;10(10):e0139905. doi: 10.1371/journal.pone.0139905. eCollection 2015.
7
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.ZMapp 逆转非人灵长类动物的晚期埃博拉病毒病。
Nature. 2014 Oct 2;514(7520):47-53. doi: 10.1038/nature13777. Epub 2014 Aug 29.
8
Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge.具有人源框架的合成抗体可保护小鼠免受致死性苏丹埃博拉病毒攻击。
ACS Chem Biol. 2014 Oct 17;9(10):2263-73. doi: 10.1021/cb5006454. Epub 2014 Aug 26.
9
Ebola virus vaccines: an overview of current approaches.埃博拉病毒疫苗:现有方法概述。
Expert Rev Vaccines. 2014 Apr;13(4):521-31. doi: 10.1586/14760584.2014.885841. Epub 2014 Feb 27.
10
Construction of human antibody gene libraries and selection of antibodies by phage display.人抗体基因文库的构建及通过噬菌体展示进行抗体筛选。
Methods Mol Biol. 2014;1060:215-43. doi: 10.1007/978-1-62703-586-6_12.